Istradefylline is an adenosine A2A receptor antagonist approved in Japan in 2013 and approved in the USA in 2019 as adjunctive treatment to levodopa/carbidopa in patients with PD experiencing OFF episodes. The gene discussed is ADORA2A; the disease is Parkinson disease.